Gcg-XTEN: An improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Geething, Nathan C ^a   To, Wayne ^a   Spink, Benjamin J ^a   Scholle, Michael D ^a   Wang, Chia Wei ^a   Yin, Yong ^a   Yao, Yi ^a   Schellenberger, Volker ^a   Cleland, Jeffrey L ^b   Stemmer, Willem P C ^a   Silverman, Joshua ^a  

^a Amunix Inc   (United States)

^b Versartis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HYBRID PROTEIN; INSULIN; PLACEBO; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG STABILITY; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VIVO STUDY; MONKEY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ANIMAL; DRUG EFFECT; HALF LIFE TIME; HAPLORHINI; PREMEDICATION;

CANIS FAMILIARIS; MACACA FASCICULARIS;

ANIMALS; BLOOD GLUCOSE; DOGS; GLUCAGON; HALF-LIFE; HAPLORHINI; HYPOGLYCEMIA; INSULIN; PREMEDICATION;

EID: 77956313886     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010175     Document Type: Article

References (22)

1. American Diabetes Association (2008) Standards of medical care in diabetes- 2008. Diabetes Care 31 Suppl 1: S12-54.
2. Bulsara MK, Holman CD, Davis EA, Jones TW (2004) The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care 27: 2293-2298.
3. Davis EA, Keating B, Byrne GC, Russell M, Jones TW (1998) Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child 78: 111-115.
4. Lawson ML, Gerstein HC, Tsui E, Zinman B (1999) Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care 22 Suppl 2: B35-39.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj 321: 405-412.
6. Drucker DJ (2007) The role of gut hormones in glucose homeostasis. J Clin Invest 117: 24-32.
7. Fanelli CG, Porcellati F, Rossetti P, Bolli GB (2006) Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab Cardiovasc Dis 16 Suppl 1: S28-34.
8. Schultes B, Jauch-Chara K, Gais S, Hallschmid M, Reiprich E, et al. (2007) Defective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus. PLoS Med 4: e69.
9. Tu E, Twigg SM, Duflou J, Semsarian C (2008) Causes of death in young Australians with type 1 diabetes: a review of coronial postmortem examinations. Med J Aust 188: 699-702.
10. Bode BW, Schwartz S, Stubbs HA, Block JE (2005) Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 28: 2361-2366.
11. Davis EA, Keating B, Byrne GC, Russell M, Jones TW (1997) Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 20: 22-25.
12. Radan I, Rajer E, Ursic Bratina N, Neubauer D, Krzisnik C, et al. (2004) Motor activity during asymptomatic nocturnal hypoglycemia in adolescents with type 1 diabetes mellitus. Acta Diabetol 41: 33-37.
13. Wiltshire EJ, Newton K, McTavish L (2006) Unrecognised hypoglycaemia in children and adolescents with type 1 diabetes using the continuous glucose monitoring system: prevalence and contributors. J Paediatr Child Health 42: 758-763.
14. Cryer PE, Gerich JE (1983) Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine. Diabetes Care 6: 95-99.
15. Davis MR, Shamoon H (1991) Counterregulatory adaptation to recurrent hypoglycemia in normal humans. J Clin Endocrinol Metab 73: 995-1001.
16. Glucagon Package Insert. Eli Lilly, Inc. (2009)
17. Edelman SV Very-low-dose glucagon may prevent nocturnal hypoglycemia; American Diabetes Association Annual Meeting, Chicago.
18. Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27: 1186-1190.
19. Bray GA (2000) Afferent signals regulating food intake. Proc Nutr Soc 59: 373-384.
20. Zick R, Petersen B, Richter M, Haug C (2007) Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther 9: 483-492.
21. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol.
22. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30: 1487-1493.